Ovarian Cancer
An Introduction to Ovarian Cancer
Before 2016 the prognosis for patients with ovarian cancer was poor, and treatment options were limited. However, the introduction of bevacizumab followed by PARP inhibitors transformed outcomes in patients with BRCA1/2 mutation. Anti-angiogenic agents, immuno-oncology agents, combinations of these agents and hyperthermic intraperitoneal chemotherapy are currently being investigated and show promise for the future.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.
Our supporting partners do not constitute an endorsement of the content on this page.
This year, we are celebrating our inaugural touchONCOLOGY Future Leaders to recognize the outstanding talent that has entered our field in recent years. These individuals are set to innovate and transform oncology and haematology in the years to come.
Highlights from ESGO 2024, featuring the latest data and insights presented at the meeting.
Watch this two-part activity exploring the latest data on the use of PARP inhibitors in first-line maintenance therapy in ovarian cancer. Filmed following the ESGO European Congress on Gynaecological Oncology 2022. Part 1: Watch gynaecological cancer expert Prof. Jonathan Ledermann review key data from ESGO 2022 Watch Now Part 2: Watch leading experts consider what these data may mean for global and regional practice Select An Interview
Watch this two-part activity exploring recent developments in the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022. Part 1: Watch gynaecological cancer expert Prof. Isabelle Ray-Coquard review key data from the SGO Virtual Annual Meeting 2021 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
Watch this two-part activity exploring recent developments on the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Virtual Annual Meeting 2021. Part 1: Watch gynaecological cancer expert Dr Alexandra Leary review key data from the SGO Virtual Annual Meeting 2021 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living ...
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, ...
Ovarian cancer is a leading cause of cancer death in women worldwide, with almost 300,000 cases diagnosed in 2018.1 If diagnosed and treated at stage I, the 5-year relative survival rate is 92%. However, only about 15% of ovarian cancers are diagnosed at this ...
It is not by chance that this issue of European Oncology & Haematology is opened by an editorial from Suhag, dedicated to the oncological scenario in developing countries, warning that there is “little light at the end of the tunnel”. ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
